Jennifer Doudna's startup Aurora Therapeutics aims to scale personalized gene-editing treatments for rare diseases like PKU using CRISPR technology and a new FDA pathway that expedites approval for bespoke therapies based on limited patient data.
The article discusses skepticism around Trump's proposed plan to pressure insurers into lowering prices, with critics arguing it oversimplifies a complex healthcare issue and may not lead to significant relief for families, while some politicians remain cautiously optimistic.
A retired San Francisco firefighter with stage 4 lung cancer is seeking city intervention after Blue Shield denied his treatment, raising concerns about insurance practices and access to lifesaving care.
The upcoming JPMorgan Healthcare Conference will showcase industry updates on drug pipelines, M&A activity, and the impact of recent drug pricing deals, with a focus on managing patent expirations, obesity treatments, and potential new drug developments from major pharma companies like Bristol Myers Squibb, Merck, Novo Nordisk, and Eli Lilly.
Amazon Pharmacy now offers Novo Nordisk's Wegovy weight-loss pill through insurance and cash options, with prices starting at $25 for insured and $149 for cash-paying customers, expanding access via kiosks and collaborations with telehealth providers, as the drug gains FDA approval and aims to attract new consumers seeking an alternative to injectable treatments.
Menlo Ventures has invested $16 million in Aurora Therapeutics, co-founded by CRISPR pioneer Jennifer Doudna and Fyodor Urnov, to develop personalized CRISPR therapies targeting rare diseases like PKU, leveraging recent regulatory and technological advances to make treatments for ultra-rare conditions more feasible.
Texas has eased licensing requirements for foreign-trained doctors to address a projected physician shortage, allowing them to practice after supervised work in underserved areas, aiming to increase healthcare access in rural and underserved communities.
An increasing number of patients are ordering their own lab tests online without medical consultation, leading to challenges for doctors in interpreting results and integrating them into care, as patients seek immediate health insights outside traditional medical pathways.
U.S. Rep. Monica De La Cruz, a Republican from Texas, joined Democrats in passing a three-year extension of ACA subsidies, a move that could influence upcoming elections and faces uncertain prospects in the Senate. The measure aims to address rising healthcare costs and protect millions of Texans who benefit from the subsidies, despite opposition from some Republicans.
OpenAI has launched ChatGPT for Healthcare, a new suite of AI tools powered by GPT-5 designed for medical professionals, offering features like patient data review and integration with existing systems, aiming to reduce administrative burdens and support clinical decision-making while emphasizing HIPAA compliance. The tools are already being adopted by major institutions, reflecting the growing use of AI in healthcare to improve efficiency amid ongoing staff shortages.
Krystal Biotech announced positive interim results from its Phase 1 trial of KB407, a gene therapy for cystic fibrosis, confirming successful lung delivery and expression of wild-type CFTR protein across diverse patients, paving the way for a larger, repeat-dosing study expected to start in 2026.
CMS has approved Nevada Donor Network to take over organ procurement services in South Florida after decertifying the University of Miami's provider due to noncompliance, ensuring continued organ donation and transplantation services during the transition.
Eli Lilly's drug Zepbound, when combined with its immunology therapy Taltz, showed promise in reducing symptoms of psoriatic arthritis in obese patients, suggesting potential new uses for the weight loss drug, though its impact on prescribing patterns remains uncertain.
The article explains TRICARE's policies on allowable charges and balance billing, highlighting the differences between network, participating, and nonparticipating providers, and advising beneficiaries on how to avoid overpaying for healthcare services under TRICARE.
As Gavin Newsom's final year as California governor approaches, he faces the challenge of fulfilling his ambitious promises on housing, homelessness, and healthcare, amid political and budgetary hurdles, while positioning himself for a potential presidential run.